Alaunos Therapeutics, Inc. (TCRT)

Alaunos Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019	2018 - 2004
Revenue	0.01	2.92	0.4	0	0	Upgrade
Revenue Growth (YoY)	-99.83%	634.17%	-	-	-	Upgrade
Gross Profit	0.01	2.92	0.4	0	0	Upgrade
Selling, General & Admin	12.22	13.14	27.56	27.67	19.53	Upgrade
Research & Development	16.28	25.02	49.64	52.7	38.33	Upgrade
Other Operating Expenses	5.77	-0.13	0.74	0	0	Upgrade
Operating Expenses	34.27	38.03	77.95	80.36	57.86	Upgrade
Operating Income	-34.27	-35.11	-77.55	-80.36	-57.86	Upgrade
Interest Expense / Income	1.92	3.15	1.19	0	0	Upgrade
Other Expense / Income	-1.05	-0.53	0.01	-0.39	59.94	Upgrade
Pretax Income	-35.14	-37.73	-78.75	-79.98	-117.8	Upgrade
Net Income	-35.14	-37.73	-78.75	-79.98	-117.8	Upgrade
Shares Outstanding (Basic)	16	14	14	14	11	Upgrade
Shares Outstanding (Diluted)	16	14	14	14	11	Upgrade
Shares Change	10.50%	1.27%	2.27%	24.82%	16.87%	Upgrade
EPS (Basic)	-2.20	-2.61	-5.55	-5.70	-10.50	Upgrade
EPS (Diluted)	-2.20	-2.61	-5.55	-5.70	-10.50	Upgrade
Free Cash Flow	-28.8	-29.43	-64.79	-66.79	-41.14	Upgrade
Free Cash Flow Per Share	-1.80	-2.03	-4.53	-4.78	-3.67	Upgrade
Gross Margin	100.00%	100.00%	100.00%	-	-	Upgrade
Operating Margin	-685340.00%	-1201.40%	-19484.67%	-	-	Upgrade
Profit Margin	-702800.00%	-1291.24%	-19786.68%	-	-	Upgrade
Free Cash Flow Margin	-575920.00%	-1007.02%	-16279.15%	-	-	Upgrade
EBITDA	-30.62	-31.33	-75.32	-78.85	-117.17	Upgrade
EBITDA Margin	-612360.00%	-1072.25%	-18923.87%	-	-	Upgrade
Depreciation & Amortization	2.6	3.25	2.25	1.13	0.63	Upgrade
EBIT	-33.22	-34.58	-77.56	-79.98	-117.8	Upgrade
EBIT Margin	-664380.00%	-1183.30%	-19487.94%	-	-	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).